Genentech's Portal study shows Susvimo maintains vision and retinal drying in wet AMD patients over five years with biannual ...

R oche’s Genentech has reported new five-year data from the Phase III Portal trial, confirming the safety, durability, and ...

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause ...

Basel, 04 February 2025- Roche announced today that the US Food and Drug Administration has approved Susvimo ® 100 mg/mL for the treatment of diabetic macular edema, a leading cause of vision ...

Two-year Phase III data presented at ASRS 2024 show Susvimo’ s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy Safety data were consistent ...

Susvimo is a vascular endothelial growth factor (VEGF) inhibitor indicated for patients with wet AMD who have previously responded to at least 2 intravitreal injections of a VEGF inhibitor medication.

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

“Susvimo represents a major advancement in the treatment of retinal disease, and is an important new option for patients with wet AMD,” said Carl Regillo, MD, Chief of Retina Service at Wills ...

The Susvimo implant and the procedures associated with inserting, filling, refilling, and (if medically necessary) removing the implant can cause other serious side effects, including: ...

The Susvimo implant and the procedures associated with inserting, filling, refilling, and (if medically necessary) removing the implant can cause other serious side effects, including: ...

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration: Basel Monday, August 4, 2025, 11:00 Hrs [ ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the ...